drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T-cell)
drug_description
A single-dose allogeneic anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy using donor-derived T cells engineered to target CD19 on B cells, inducing profound B-cell depletion to suppress autoantibody production and reset humoral immunity in refractory SLE; administered after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells engineered with an anti-CD19 chimeric antigen receptor recognize and kill CD19+ B cells/plasmablasts, causing profound B-cell depletion, suppression of autoantibody production, and reset of humoral immunity; administered after lymphodepleting chemotherapy.
drug_name
BRL-301
nct_id_drug_ref
NCT05988216